Oxidative Stress in Hypertension and Chronic Kidney Disease: Role of Angiotensin II

Seminars in Nephrology

Volumn 24, Issue 2, 2004, Pages 101-114

  Agarwal, Rajiv ^a   Campbell, Ruth C ^b   Warnock, David G ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CATALASE; CYCLOSPORIN; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ENALAPRIL; EXP 3179; FLUINDOSTATIN; GLUTATHIONE PEROXIDASE; IMMUNOSUPPRESSIVE AGENT; LISINOPRIL; LOSARTAN; MALONALDEHYDE; NITRIC OXIDE SYNTHASE; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; TACROLIMUS; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; XANTHINE OXIDASE;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIETARY INTAKE; DISEASE ASSOCIATION; DNA DAMAGE; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; JUXTAGLOMERULAR APPARATUS; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIPID PEROXIDATION; MICROALBUMINURIA; NEPHRON; NEPHROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; TRANSGENIC ANIMAL; URETER OBSTRUCTION;

EID: 1642308699     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2003.11.008     Document Type: Article

References (70)

1. Griendling KK, Sorescu D, Lassegue B, et al: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20:2175-2183, 2000
2. 2 in vitro and in vivo and reduce menadione-induced DNA injury and cytotoxicity. Am J Physiol 268:C227-C236, 1995
3. Varma SD, Devamanoharan PS: Excretion of hydrogen peroxide in human urine. Free Radic Res 8:73-78, 1990
4. Bruzzi I, Benigni A, Remuzzi G: Role of increased glomerular protein traffic in the progression of renal failure. Kidney Int Suppl 62:S29-S31, 1997
5. Agarwal R: Proinflammatory effects of oxidative stress in chronic kidney disease: Role of additional angiotensin II blockade. Am J Physiol Renal Physiol 284:F863-F869, 2003
6. Klahr S, Morrissey JJ: The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 75:S7-S14, 2000 (suppl)
7. Haugen E, Nath KA: The involvement of oxidative stress in the progression of renal injury. Blood Purif 17:58-65, 1999
8. Schnackenberg CG: Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 282:R335-R342, 2002
9. Jaimes EA, Galceran JM, Raij L: Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 54:775-784, 1998
10. Hannken T, Schroeder R, Stahl RA, et al: Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 54:1923-1933, 1998
11. Wilcox CS: Reactive oxygen species: Roles in blood pressure and kidney function. Curr Hypertens Rep 4:160-166, 2002
12. Haugen EN, Croatt AJ, Nath KA: Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 58:144-152, 2000
13. Kawada N, Imai E, Karber A, et al: A mouse model of angiotensin II slow pressor response: Role of oxidative stress. J Am Soc Nephrol 13:2860-2868, 2002
14. Nishiyama A, Fukui T, Fujisawa Y, et al: Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 37:77-83, 2001
15. Nagase M, Ando K, Nagase T, et al: Redox-sensitive regulation of lox-1 gene expression in vascular endothelium. Biochem Biophys Res Commun 281:720-725, 2001
16. Delbosc S, Cristol JP, Descomps B, et al: Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 40:142-147, 2002
17. Diep QN, Amiri F, Touyz RM, et al: PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 40:866-871, 2002
18. Virdis A, Neves MF, Amiri F, et al: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504-510, 2002
19. Chabrashvili T, Kitiyakara C, Blau J, et al: Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285:R117-R124, 2003
20. Mervaala EM, Cheng ZJ, Tikkanen I, et al: Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 37:414-418, 2001
21. Wang HD, Xu S, Johns DG, et al: Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 88:947-953, 2001
22. Rugale C, Delbosc S, Cristol JP, et al: Sodium restriction prevents cardiac hypertrophy and oxidative stress in angiotensin II hypertension. Am J Physiol Heart Circ Physiol 284:H1744-H1750, 2003
23. Cheng ZJ, Vaskonen T, Tikkanen I, et al: Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 37:433-439, 2001
24. Lerman LO, Nath KA, Rodriguez-Porcel M, et al: Increased oxidative stress in experimental renovascular hypertension. Hypertension 37:541-546, 2001
25. Welch WJ, Baumgartl H, Lubbers D, et al: Renal oxygenation defects in the spontaneously hypertensive rat: Role of AT1 receptors. Kidney Int 63:202-208, 2003
26. Welch WJ, Mendonca M, Aslam S, et al: Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the post-clipped 2K, 1C kidney. Hypertension 41:692-696, 2003
27. Welch WJ, Wilcox CS: AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 59:1257-1263, 2001
28. Rodriguez-Iturbe B, Quiroz Y, Nava M, et al: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282:F191-F201, 2002
29. Quiroz Y, Pons H, Gordon KL, et al: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 281:F38-F47, 2001
30. Rodriguez-Iturbe B, Pons H, Quiroz Y, et al: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59:2222-2232, 2001
31. Rodriguez-Iturbe B, Quiroz Y, Herrera-Acosta J, et al: The role of immune cells infiltrating the kidney in the pathogenesis of salt-sensitive hypertension. J Hypertens 20:S9-S14, 2002 (suppl 3)
32. Bapat S, Post JA, Braam B, et al: Visualizing tubular lipid peroxidation in intact renal tissue in hypertensive rats. J Am Soc Nephrol 13:2990-2996, 2002
33. Kitamoto S, Egashira K, Kataoka C, et al: Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 18:1795-1800, 2000
34. Chade AR, Rodriguez-Porcel M, Rippentrop SJ, et al: Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. Am J Hypertens 16:111-115, 2003
35. Onozato ML, Tojo A, Goto A, et al: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACE1 and ARB. Kidney Int 61:186-194, 2002
36. Jones EA, Shahed A, Shoskes DA: Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin II inhibition in ureteral obstruction. Urology 56:346-351, 2000
37. Padi SS, Chopra K: Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res 45:413-420, 2002
38. Padi SS, Chopra K: Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron 92:685-692, 2002
39. Calo LA, Davis PA, Giacon B, et al: Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: Effect of ramipril. J Cardiovasc Pharmacol 40:625-631, 2002
40. de Cavanagh EM, Piotrkowski B, Basso N, et al: Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J 17:1096-1098, 2003
41. Hannken T, Schroeder R, Zahner G, et al: Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): Role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 11:1387-1397, 2000
42. Lodha S, Dani D, Mehta R, et al: Angiotensin II-induced mesangial cell apoptosis: Role of oxidative stress. Mol Med 8:830-840, 2002
43. Mundel P, Shankland SJ: Podocyte biology and response to injury. J Am Soc Nephrol 13:3005-3015, 2002
44. Gloy J, Henger A, Fischer KG, et al: Angiotensin II modulates cellular functions of podocytes. Kidney Int 67:S168-S170, 1998 (suppl)
45. Liu H, Bigler SA, Henegar JR, et al: Cytochrome P450 2B1 mediates oxidant injury in puromycin-induced nephrotic syndrome. Kidney Int 62:868-876, 2002
46. Gwinner W, Landmesser U, Brandes RP, et al: Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 8:1722-1731, 1997
47. Djordjevic VB, Cosic V, Pavlovic D, et al: Does captopril change oxidative stress in puromycin aminonucleoside nephropathy? Ren Fail 22:535-544, 2000
48. Lombardi DM, Viswanathan M, Vio CP, et al: Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent. Nephron 87:66-74, 2001
49. Keidar S, Heinrich R, Kaplan M, et al: Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages. J Renin Angiotensin Aldosterone Syst 3:24-30, 2002
50. Yanagitani Y, Rakugi H, Okamura A, et al: Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 33:335-339, 1999
51. Mazza F, Goodman A, Lombardo G, et al: Heme oxygenase-1 gene expression attenuates angiotensin II-mediated DNA damage in endothelial cells. Exp Biol Med (Maywood) 228:576-583, 2003
52. Pueyo ME, Gonzalez W, Nicoletti A, et al: Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20:645-651, 2000
53. Mueller C, Baudler S, Welzel H, et al: Identification of a novel redox-sensitive gene, Id3, which mediates angiotensin II-induced cell growth. Circulation 105:2423-2428, 2002
54. Schieffer B, Luchtefeld M, Braun S, et al: Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 87:1195-1201, 2000
55. Higashi Y, Sasaki S, Nakagawa K, et al: Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 346:1954-1962, 2002
56. Minuz P, Patrignani P, Gaino S, et al: Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106:2800-2805, 2002
57. Wassmann S, Hilgers S, Laufs U, et al: Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 22:1208-1212, 2002
58. Annuk M, Zilmer M, Lind L, et al: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:2747-2752, 2001
59. Touyz RM, Schiffrin EL: Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: Role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 19:1245-1254, 2001
60. Quinones-Galvan A, Pucciarelli A, Fratta-Pasini A, et al: Effective blood pressure treatment improves LDL-cholesterol susceptibility to oxidation in patients with essential hypertension. J Intern Med 250:322-326, 2001
61. Hussein O, Shneider J, Rosenblat M, et al: Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: Studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 40:28-34, 2002
62. Sadoshima J: Novel AT(1) receptor-independent functions of losartan. Circ Res 90:754-756, 2002
63. Nunez A, Gomez J, Zalba LR, et al: Losartan inhibits in vitro platelet activation: Comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 1:175-179, 2000
64. Kalinowski L, Matys T, Chabielska E, et al: Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 40:521-527, 2002
65. Schwemmer M, Sommer O, Bassenge E: Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther 15:301-307, 2001
66. Kramer C, Sunkomat J, Witte J, et al: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res 90:770-776, 2002
67. Chlopicki S, Koda M, Chabielska E, et al: Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol 51:715-722, 2000
68. Buczko W, Matys T, Pawlak R, et al: Studies on the antithrombotic action of ATI receptor antagonists. Med Sci Monit 7:600-605, 2001
69. Monton M, Jimenez A, Nunez A, et al: Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 35:906-913, 2000
70. Jimenez AM, Monton M, Garcia R, et al: Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: Comparison of losartan, candesartan, and valsartan. J Cardiovasc Pharmacol 37:406-412, 2001